New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)’s Effect on Bone Quality in Osteoporotic Patients

3D Images Provide New Approach to Monitoring Bone Changes
MUNICH, June 28, 2010 – Interim data from a prospective Investigator Initiated Trial
(IIT) presented today at the ECTS, the 37th European Symposium on Calcified
Tissues, in Glasgow, demonstrates that EVISTA(R) (raloxifene 60mg;
once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the
treatment and prevention of osteoporosis in [...]

Kowa Company, Ltd. Grants Abbott Exclusive Rights to Market Pitavastatin Calcium, a Lipid-lowering Drug, in Australia and New Zealand

WOKINGHAM, England, June 28, 2010 – Following an enthusiastic expansion programme into new markets, Kowa
Company, Ltd. (President: Yoshihiro Miwa), headquartered in Nagoya, Japan,
has granted Abbott, headquartered in Illinois, USA the exclusive license to
distribute and market pitavastatin calcium (brand name Livalo), a
lipid-lowering drug, in Australia and New Zealand. This agreement means that
pitavastatin will now be [...]

Enzymes Gain Importance as Process Aids in Food Applications, Finds Frost & Sullivan

LONDON, June 28, 2010 – During the economic slowdown in 2009, food enzymes were successfully
positioned as cost savers and process efficiency improvers in many
application segments. This strategy, along with increased R&D efforts, is
expected to continue to attract new applications such as interesterification
for the reduction of trans fats and as 'meat glue' (transglutaminases). While
the increased [...]

Chasing Happiness: Why Feeling Good Remains Elusive

SAN FRANCISCO, June 28, 2010 – Want happiness? While studies indicate that lots of friends, a high
paying job, or even passing years may create a higher likelihood of feeling
"happy," a reliable recipe for lasting happiness remains elusive, says The
Gnostic Movement. Lasting happiness will be the focus of a global Gnostic
event on July 10 in [...]

Gastrointestinal Disorders Therapeutics to 2016 – High Unmet Needs Triggering Strong Growth in Crohn’s Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports

DALLAS, June 28, 2010 – ReportsandReports announces it will carry the Gastrointestinal Disorders
Therapeutics to 2016 – High Unmet Needs Triggering Strong Growth in Crohn's
Disease and Irritable Bowel Syndrome Markets Market Research Report in its
store.

Browse the complete Report on:
www.reportsandreports.com/market-reports/gastrointestinal-disorders-th
erapeutics-to-2016-high-unmet-need/
GBI Research's report, "Gastrointestinal disorders therapeutics, analysis
and forecasts to [...]

Indian Multinational Company Confirms USD 6 Million Order to Set up Industrial Waste Water Treatment Plants in Africa

CHENNAI, India, June 28, 2010 – Shivsu Canadian Clear International Ltd, a leading water technology
solution provider, has completed an order worth USD 6 million from the
private organizations and Government of Africa to set up industrial waste
water treatment plants in Kenya, Tanzania and Ethiopia. The company will be
involved in design, manufacture, supply and installation of [...]

Astellas Announces Oral Presentation of SGLT2 Inhibitor Detailing Safety and Efficacy in Patients With Type 2 Diabetes at the American Diabetes Association Meeting

TOKYO, June 28, 2010 – Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi
Nogimori, "Astellas") announced that the company presented results from a
Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor,
at the 70th Scientific Sessions of the American Diabetes Association (ADA) on
June 26, 2010 (EST). ASP1941 is designed to block the re-absorption [...]

The National Institute for Health & Clinical Excellence (NICE) Approves the Use of Radiofrequency Ablation for Treatment of Barrett’s Esophagus

Interventional Procedures (IPAC) Guidelines from NICE in the UK include Radiofrequency Ablation (RFA) for eradication of high grade dysplasia in patients with Barrett's Esophagus.

SUNNYVALE, California, June 28, 2010 – BARRX Medical Inc., a world leader in products to treat pre-cancerous
tissue in the esophagus, reported today that the National Institute for
Health and Clinical Excellence (NICE) [...]

Power Market in Western Europe to 2020 – Increasing Focus on Renewable Power to Change the Energy Mix Now Available at ReportsandReports

DALLAS, June 28, 2010 – ReportsandReports announces it will carry the Power Market in Western
Europe to 2020 – Increasing Focus on Renewable Power to Change the Energy Mix
Market Research Report in its store.

Browse the complete Report on:
www.reportsandreports.com/market-reports/power-market-in-western-europ
e-to-2020-increasing-focus-on-rene/
GBI Research's report, "Power Market in Western Europe to 2020:
Increasing [...]

Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline

Second Deal in Six Months Expands CNS Portfolio to Four Programs
MAPLE GROVE, Minnesota, June 28, 2010 – Upsher-Smith Laboratories, Inc. today announced an agreement with Ikano
Therapeutics, Inc. to obtain exclusive global rights to ITI-111, Ikano's
nasal midazolam. Under terms of the agreement, Upsher-Smith will assume all
further development, testing and clinical study of nasal midazolam as [...]

Findings From Global Survey Help Understand Fertility Trends And Barriers to Seeking Medical Help Against Infertility

Over 10,000 Responded to the Largest International Study Aimed at Understanding the Decision-making Process of Couples Trying to Conceive

ROME, June 28, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today
announced the outcomes of the Global survey "Starting Families" at the 26th
edition of the annual meeting of the European Society of Human [...]

Frankfurt To Host World’s Largest Pharmaceutical Services Events In 2011

AMSTERDAM, June 28, 2010 – Leading events organiser UBM International Media today announced that its
flagship CPhI Worldwide tradeshow will return to Frankfurt, Germany for 2011.
Along with co-hosted events – P-MEC Europe for equipment, machinery and
technology; ICSE for contract services and packaging; and BioPh Europe for
the biopharma sector – the world's leading pharma services industry [...]

Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company

CASTRES, France, June 28, 2010 – Mr Jean-Pierre Garnier will step down on September 1st 2010,
two years after having been appointed CEO of the Pierre Fabre Group.

"The Company is in excellent health, and is poised to
experience a bright future ; I am glad to have contributed to its success and
I [...]

Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards

Outstanding Young Women Biologists, Chemists, Physicists and Mathematicians Recognized Across the Developing World

BEIJING, June 27, 2010 – The Elsevier Foundation, TWAS and TWOWS announced today that they are
recognizing twelve talented women scientists from Africa, the Middle East,
Asia, Latin America and the Caribbean for their research excellence. The
announcement was made at the Third World Organization [...]

Results From Study of Vascular Calcification in Dialysis Patients Presented in Late-Breaking Clinical Trial Session at ERA-EDTA 2010 Congress

MUNICH, June 26, 2010 – Results from the ADVANCE study presented in a late breaking clinical
trial session at the ERA-EDTA 2010 Congress provide new insights into the
management of secondary hyperparathyroidism (SHPT) in chronic kidney disease
(CKD) patients. ADVANCE (A randomiseD VAscular calcificatioN study to
evaluate the effects of CinacalcEt) is a randomised, controlled open label
study to [...]

ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control In Treatment-Naive Adults With Type 2 Diabetes

Not for US Media
ORLANDO, Florida, June 26, 2010 – Bristol-Myers Squibb Company (NYSE: BMY)
and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a
Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy
with metformin, which produced long-term glycemic improvement [as measured
by glycosylated hemoglobin level (HbA1c)] in treatment-naive adults with
type 2 diabetes mellitus inadequately [...]

52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To Titrated Glipizide When Added To Metformin In Reducing Glycosylated Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus

Not for US Media
ORLANDO, Florida, June 26, 2010 – Bristol-Myers Squibb Company (NYSE: BMY)
and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b
study in adults with type 2 diabetes who had inadequate glycemic control on
metformin therapy plus diet and exercise. This study found that the addition
of ONGLYZA(TM) (saxagliptin) 5 mg to existing [...]

Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin

Not for US Media
ORLANDO, Florida, June 26, 2010 – Results from a 24-week Phase 3 clinical
study demonstrated that the addition of the investigational drug
dapagliflozin achieved reductions in the primary endpoint, glycosylated
hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients
who were treated with insulin (with or without oral anti-diabetes medications
(OADs)), compared to placebo plus [...]

Merck Serono Calls for Entries to Real MS – Your Story, a Global Competition to Raise Awareness of Multiple Sclerosis

Campaign Website and Global Script Concept Competition Launch Today
GENEVA, June 25, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
today announces the start of the Real MS: Your Story competition, with the
campaign website (www.realmsvoices.com) now open for entry
submissions. Real MS: Your Story is the first element of Real MS, a global
multiple sclerosis [...]

Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union

CAMBRIDGE, Massachusetts, June 25, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announced today that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency adopted a
positive opinion on the marketing authorisation for VPRIV(TM) (velaglucerase
alfa), the company's enzyme replacement therapy (ERT) for the treatment of
type 1 Gaucher [...]